Epoch Biosciences Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Epoch Biosciences Inc.
Appointments: Synthorx, BTG, Pertinax, Realm, Breath, Aerie, iOnctura, Inflazome and NBE
The week's round-up includes a new CEO at Synthorx Inc., new sales executives at Aerie Pharmaceuticals and board appointments at BTG, Pertinax Pharma, Realm Therapeutics, Breath Therapeutics, iOnctura, NBE Therapeutics and Inflazome.
Vitae partner Boehringer takes BACE inhibitor into the clinic
Boehringer Ingelheim initiated a Phase I clinical trial for the beta-secretase (BACE) inhibitor developed under a 2009 collaboration agreement with Vitae Pharmaceuticals, triggering a $14m milestone payment to the private biopharma company.
Merck gets BACE boost in Alzheimer's race
Merck & Co's MK-8931 has successfully cleared an early hurdle in the race to find a product that might treat Alzheimer's disease through beta secretase enzyme (BACE) inhibition. The firm reported positive Phase Ib results showing a quick, dose-dependent reduction in amyloid.
- Research, Analytical Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.